When was TopazBio founded?

TopazBio was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Where is TopazBio located?

TopazBio is headquartered in Cambridge, United States.

Is TopazBio a funded company?

TopazBio is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 15, 2023.

When was the latest funding round of TopazBio?

TopazBio's latest funding was a $***** Grant (prize money) round on Jul 08, 2024, with participation from 1 investor. Its primary sector is Dermatology. In United States, the Dermatology sector has seen $168M in funding in 2026 to date.

Where does TopazBio rank among its competitors?

TopazBio ranks 2619th amongst 2525 active competitors, of which 862 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was TopazBio, which secured $300K in Jul, 2024.

Who are the top competitors of TopazBio?

TopazBio's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, TopazBio secured the most recent funding round in July, 2024.

TopazBio - 2026 Company Profile, Funding & Competitors

Company Details

Developer of biological molecules using metagenomics, synthetic, and computational biology. The company focuses on overcoming discovery bottlenecks to create commercially valuable molecules. It leverages expertise in metagenomic diversity for product development. The team consists of scientists and entrepreneurs with previous experience in related fields.

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jul 08, 2024, $*****

Investors

HHS

Ranked

2619^th among 3098 competitors

Similar Companies

LEO Pharma & 146 more

View TopazBio's full profile

TopazBio has raised funding over 2 rounds. Its first funding round was on Sep 15, 2023. Its latest funding round was a Grant (prize money) round on Jul 08, 2024 for $*****. 1 investor participated in its latest round. TopazBio has 1 institutional investor.

Here is the list of recent funding rounds of TopazBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 08, 2024	5167114	Grant (prize money)	3046132	2832858	4696319	5072892
Sep 15, 2023	7958856	Grant (prize money)	8653665	8889566	7748298	HHS

Access funding benchmarks and valuations. Sign up today!

View details of TopazBio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of TopazBio include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of TopazBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
7th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
2619th	TopazBio 2018, Cambridge (United States), Funding Raised	Developer of biological molecules using metagenomics, synthetic, and computational biology	-	HHS	16/100